查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
活性药物成分市场 - 全球市场规模、份额、趋势分析、机会和预测报告，2019-2029
市场调查报告书
商品编码
1310387

活性药物成分市场 - 全球市场规模、份额、趋势分析、机会和预测报告，2019-2029

Active Pharmaceutical Ingredients Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By API ; By Manufacturer ; By Type of Drug ; By Therapeutic Area ; By Potency ; Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3个工作天内

价格
简介目录

到 2029 年，全球活性药物成分 (API) 市场有望达到 3250 亿美元

由于全球慢性病的增加、仿製药生产的扩大以及药品製造技术的进步，对具有成本效益的药物的需求不断增加，全球活性药物成分（API）市场正在蓬勃发展。

领先的战略咨询和市场研究公司 BlueWeave Consulting 最近估计，2022 年全球活性药物成分 (API) 市场价值将达到 2324 亿美元。 BlueWeave 预测，2023-2029 年预测期内，全球活性药物成分 (API) 市场规模将以 5.69% 的复合年复合成长率增长，到 2029 年达到 3246.7 亿美元。心血管疾病、癌症和糖尿病等慢性疾病的全球负担日益增加，推动了对有效且具有成本效益的治疗方案的需求。 API 构成了药物的支柱，随着治疗干预需求的增长，开发和生产这些药物对 API 的需求也会增加。此外，製药公司大力投资研发活动，以推出创新药物和治疗方法。对研发的更多关注将进一步增加对活性药物成分的需求，活性药物成分是药物开发的关键组成部分。由于技术进步和药物发现投资的增加，全球活性药物成分（API）市场预计在未来几年将出现显着增长。

该报告的详细分析提供了有关全球活性药物成分（API）市场的增长潜力、未来趋势和统计数据的信息。它还重点关注推动市场总规模预测的因素。该报告致力于为决策者提供全球活性药物成分（API）市场的最新技术趋势以及行业见解，以做出明智的战略决策。它还分析了市场的增长促进因素、挑战和竞争力。

目录

第1章研究框架

第2章执行摘要

第3章全球原料药（API）市场洞察

  • 行业价值链分析
  • DROC分析
    • 增长促进因素
      • 仿製药需求不断增长
      • 慢性病患病率上升
      • 更加註重新 API 的研发
    • 抑制因素
      • 严格的监管要求
      • 价格波动
    • 机会
      • 新兴市场需求不断增长
      • 新技术开发
    • 任务
      • 监管挑战
      • 与仿製药的竞争
  • 技术进步/最新发展
  • 监管框架
  • 波特五力分析

第4章全球活性药物成分（API）市场概述

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 通过API
      • 合成原料药
      • 生物原料药
    • 按製造商
      • 俘虏製造者
      • 经销商製造商
    • 按药物类型
      • 品牌/创新药
      • 仿製药
    • 按治疗领域
      • 心血管系统
      • 中枢神经系统（CNS）
      • 呼吸系统
      • 肿瘤学
      • 消化系统
      • 其他的
    • 按功效
      • 旧版 API
      • HPAPI
    • 按地区
      • 北美
      • 欧洲
      • 亚太地区 (APAC)
      • 拉丁美洲 (LATAM)
      • 中东和非洲 (MEA)

第5章北美活性药物成分（API）市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 通过API
    • 按製造商
    • 按药物类型
    • 按治疗领域
    • 按功效
    • 按国家/地区
      • 我们
      • 加拿大

第6章欧洲活性药物成分（API）市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 通过API
    • 按製造商
    • 按药物类型
    • 按治疗领域
    • 按功效
    • 按国家/地区
      • 德国
      • 英国
      • 意大利
      • 法国
      • 西班牙
      • 比利时
      • 俄罗斯
      • 荷兰
      • 其他欧洲国家

第7章亚太原料药（API）市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 通过API
    • 按製造商
    • 按药物类型
    • 按治疗领域
    • 按功效
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳大利亚和新西兰
      • 印尼
      • 马来西亚
      • 新加坡
      • 越南
      • 亚太地区其他地区

第8章拉丁美洲活性药物成分 (API) 市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 按国家/地区
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘鲁
      • 拉丁美洲其他地区

第9章中东和非洲原料药（API）市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 通过API
    • 按製造商
    • 按药物类型
    • 按治疗领域
    • 按功效
    • 按国家/地区
      • 沙特阿拉伯
      • 阿拉伯联合酋长国
      • 卡塔尔
      • 科威特
      • 南非
      • 尼日利亚
      • 阿尔及利亚
      • MEA 的其余部分

第10章竞争格局

  • 主要公司及其产品列表
  • 2022 年全球活性药物成分 (API) 市场份额分析
  • 通过运行参数进行竞争基准测试
  • 主要战略发展（合併、收购、合作伙伴关係等）

第11章COVID-19 对活性药物成分市场的影响

第12章公司简介（公司简介、财务矩阵、竞争格局、关键人才、主要竞争、联繫地址、战略展望、SWOT分析）

  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc.
  • Novartis International AG
  • Mylan NV
  • Aurobindo Pharma Ltd
  • Sun Pharmaceutical Industries Ltd
  • Boehringer Ingelheim GmbH
  • Dr. Reddy's Laboratories Ltd
  • Merck & Co., Inc.
  • Lonza Group Ltd
  • Bristol-Myers Squibb
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Lupin Limited
  • Cipla Ltd
  • Other Prominent Players

第13章关键战略建议

第14章调查方法

  • 定性研究
    • 初级和次级研究
  • 定量研究
  • 市场细分和数据三角测量
    • 二次调查
    • 初步调查
  • 主要调查受访者的地区分布
  • 假设和限制
简介目录
Product Code: BWC19271

Global Active Pharmaceutical Ingredients (API) Market Size Booming to Touch USD 325 Billion by 2029.

Global active pharmaceutical ingredients (API) market is flourishing due to a high demand for cost-effective medicines driven by the increasing prevalence of chronic diseases across the world, expansion of generic drug manufacturing, and advancements in drug manufacturing technology.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global active pharmaceutical ingredients (API) market size was worth USD 232.4 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global active pharmaceutical ingredients (API) market size to grow at a CAGR of 5.69% reaching a value of USD 324.67 billion by 2029. The rising global burden of chronic diseases, such as cardiovascular diseases, cancer, and diabetes, is driving the demand for effective and cost-efficient treatment options. APIs form the backbone of pharmaceutical drugs, and the growing need for therapeutic interventions will lead to an increased demand for APIs to develop and manufacture these medications. Moreover, pharmaceutical companies are investing heavily in R&D activities to introduce innovative drugs and therapies. The increasing focus on R&D will further drive the demand for APIs as they are the key components in drug development. With advancements in technology and increasing investments in novel drug discoveries, the global active pharmaceutical ingredients (API) market is expected to witness substantial growth in the coming years.

Increasing demand for generic drugs:

Generic drugs are cost-effective alternatives to branded drugs, offering the same therapeutic benefits at lower prices. This affordability makes them accessible to a larger population, driving their demand and subsequently boosting the API market. As patents expire for branded drugs, generic drug manufacturers can enter the market with their versions, utilizing APIs to produce these cost-effective alternatives. This creates opportunities for API manufacturers to supply the necessary ingredients for generic drug production. For example, when the patent for a popular branded drug expires, multiple generic manufacturers can develop their versions using the same API. This leads to increased competition, resulting in lower prices and wider availability of the drug. As a result, patients and healthcare providers can choose more affordable options, reducing healthcare costs, and increasing accessibility. A study by the World Health Organization (WHO) found that generic drugs can save up to 80% of the cost of branded drugs. The WHO also estimates that generic drugs could save the global healthcare system USD 200 billion per year. As a result, governments and healthcare systems worldwide are actively promoting the use of generic drugs to reduce healthcare expenditures. In some cases, regulations may even mandate the prescription of generic drugs whenever possible. This policy support further drives the demand for generic drugs and, consequently, the growth of global API market. The growing demand for generic drugs is also fueled by the increasing prevalence of chronic diseases globally. As the population ages and chronic conditions become more prevalent, the need for cost-effective treatment options rises. Generic drugs, enabled by APIs, play a vital role in meeting the increasing demand and providing affordable healthcare solutions.

Segmental Information:

Global Active Pharmaceutical Ingredients (API) Market - By Therapeutic Area:

Based on therapeutic area, the global active pharmaceutical ingredients (API) market is segmented into the cardiovascular system, central nervous system, respiratory system, oncology, gastrointestinal system, and others. The cardiovascular system segment held the largest market share in the global active pharmaceutical ingredients (API) market, due to the prominence of cardiovascular drugs and therapies. Cardiovascular diseases, including heart diseases, stroke, and hypertension, are prevalent worldwide and remain one of the leading causes of morbidity and mortality. The increasing incidence of cardiovascular disorders, coupled with the aging population and lifestyle changes, drives the demand for pharmaceutical interventions in this therapeutic area. As a result, there is a substantial need for API-based medications targeting the cardiovascular system. The cardiovascular API market benefits from the continuous development of innovative treatments and therapies. Furthermore, cardiovascular drugs often require long-term treatment, contributing to a sustained demand for APIs in the cardiovascular therapeutic area. Patients with cardiovascular conditions typically require medications that help regulate blood pressure, manage cholesterol levels, and prevent blood clots. As these drugs are frequently prescribed and used over extended periods, the demand for cardiovascular APIs remains high. Governments and healthcare organizations worldwide also prioritize cardiovascular health due to its substantial economic and healthcare burden. Public health initiatives and awareness campaigns further drive the demand for cardiovascular medications, boosting the market growth for cardiovascular APIs.

Impact of COVID-19 on Global Active Pharmaceutical Ingredients Market:

The COVID-19 pandemic had a mixed impact on the global active pharmaceutical ingredients (API) market. While the demand for certain APIs surged due to the production of drugs and vaccines to combat the virus, other segments experienced disruptions. Supply chain disruptions, restrictions on trade, and raw material shortages impacted API manufacturing and distribution. The increased focus on healthcare preparedness and vaccine development during the pandemic drove the demand for APIs. The pandemic also highlighted the importance of domestic API production, leading to efforts by governments to strengthen local manufacturing capabilities. Overall, the COVID-19 pandemic reshaped the API market dynamics, emphasizing the need for resilient supply chains and domestic manufacturing capacities.

Competitive Landscape:

The global active pharmaceutical ingredients (API) market is fragmented, with many players serving the market. The key players dominating the global active pharmaceutical ingredients (API) market include Teva Pharmaceutical Industries Ltd, Pfizer Inc., Novartis International AG, Mylan N.V., Aurobindo Pharma Ltd, Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim GmbH, Dr Reddy's Laboratories Ltd, Merck & Co., Inc., Lonza Group Ltd, Bristol-Myers Squibb, GlaxoSmithKline plc, AbbVie Inc., Lupin Limited, and Cipla Ltd. The key marketing strategies adopted by the players are facility expansion, product diversification, alliances, collaborations, partnerships, and acquisition to expand their customer reach and gain a competitive edge in the overall market.

The report's in-depth analysis provides information about growth potential, upcoming trends, and the Global Active Pharmaceutical Ingredients (API) Market statistics. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Active Pharmaceutical Ingredients (API) Market along with industry insights to help decision-makers make sound strategic decisions. The report also analyses the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Active Pharmaceutical Ingredients (API) Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing demand for generic drugs
      • 3.2.1.2. Rising prevalence of chronic diseases
      • 3.2.1.3. Growing focus on research and development of new APIs
    • 3.2.2. Restrains
      • 3.2.2.1. Stringent regulatory requirements
      • 3.2.2.2. Price volatility
    • 3.2.3. Opportunities
      • 3.2.3.1. Growing demand from emerging markets
      • 3.2.3.2. Development of new technologies
    • 3.2.4. Challenges
      • 3.2.4.1. Regulatory challenges
      • 3.2.4.2. Competition from generics
  • 3.3. Technology Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Active Pharmaceutical Ingredients (API) Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share and Forecast
    • 4.2.1. By API
      • 4.2.1.1. Synthetic API
      • 4.2.1.2. Biological API
    • 4.2.2. By Manufacturer
      • 4.2.2.1. Captive Manufacturers
      • 4.2.2.2. Merchant Manufacturers
    • 4.2.3. By Type of Drug
      • 4.2.3.1. Branded/Innovator Drugs
      • 4.2.3.2. Generic Drugs
    • 4.2.4. By Therapeutic Area
      • 4.2.4.1. Cardiovascular System
      • 4.2.4.2. Central Nervous System (CNS)
      • 4.2.4.3. Respiratory System
      • 4.2.4.4. Oncology
      • 4.2.4.5. Gastrointestinal System
      • 4.2.4.6. Others
    • 4.2.5. By Potency
      • 4.2.5.1. Traditional API
      • 4.2.5.2. HPAPI
    • 4.2.6. By Region
      • 4.2.6.1. North America
      • 4.2.6.2. Europe
      • 4.2.6.3. Asia Pacific (APAC)
      • 4.2.6.4. Latin America (LATAM)
      • 4.2.6.5. Middle East and Africa (MEA)

5. North America Active Pharmaceutical Ingredients (API) Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By API
    • 5.2.2. By Manufacturer
    • 5.2.3. By Type of Drug
    • 5.2.4. By Therapeutic Area
    • 5.2.5. By Potency
    • 5.2.6. By Country
      • 5.2.6.1. United States
      • 5.2.6.1.1. By API
      • 5.2.6.1.2. By Manufacturer
      • 5.2.6.1.3. By Type of Drug
      • 5.2.6.1.4. By Therapeutic Area
      • 5.2.6.1.5. By Potency
      • 5.2.6.2. Canada
      • 5.2.6.2.1. By API
      • 5.2.6.2.2. By Manufacturer
      • 5.2.6.2.3. By Type of Drug
      • 5.2.6.2.4. By Therapeutic Area
      • 5.2.6.2.5. By Potency

6. Europe Active Pharmaceutical Ingredients (API) Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By API
    • 6.2.2. By Manufacturer
    • 6.2.3. By Type of Drug
    • 6.2.4. By Therapeutic Area
    • 6.2.5. By Potency
    • 6.2.6. By Country
      • 6.2.6.1. Germany
      • 6.2.6.1.1. By API
      • 6.2.6.1.2. By Manufacturer
      • 6.2.6.1.3. By Type of Drug
      • 6.2.6.1.4. By Therapeutic Area
      • 6.2.6.1.5. By Potency
      • 6.2.6.2. United Kingdom
      • 6.2.6.2.1. By API
      • 6.2.6.2.2. By Manufacturer
      • 6.2.6.2.3. By Type of Drug
      • 6.2.6.2.4. By Therapeutic Area
      • 6.2.6.2.5. By Potency
      • 6.2.6.3. Italy
      • 6.2.6.3.1. By API
      • 6.2.6.3.2. By Manufacturer
      • 6.2.6.3.3. By Type of Drug
      • 6.2.6.3.4. By Therapeutic Area
      • 6.2.6.3.5. By Potency
      • 6.2.6.4. France
      • 6.2.6.4.1. By API
      • 6.2.6.4.2. By Manufacturer
      • 6.2.6.4.3. By Type of Drug
      • 6.2.6.4.4. By Therapeutic Area
      • 6.2.6.4.5. By Potency
      • 6.2.6.5. Spain
      • 6.2.6.5.1. By API
      • 6.2.6.5.2. By Manufacturer
      • 6.2.6.5.3. By Type of Drug
      • 6.2.6.5.4. By Therapeutic Area
      • 6.2.6.5.5. By Potency
      • 6.2.6.6. Belgium
      • 6.2.6.6.1. By API
      • 6.2.6.6.2. By Manufacturer
      • 6.2.6.6.3. By Type of Drug
      • 6.2.6.6.4. By Therapeutic Area
      • 6.2.6.6.5. By Potency
      • 6.2.6.7. Russia
      • 6.2.6.7.1. By API
      • 6.2.6.7.2. By Manufacturer
      • 6.2.6.7.3. By Type of Drug
      • 6.2.6.7.4. By Therapeutic Area
      • 6.2.6.7.5. By Potency
      • 6.2.6.8. The Netherlands
      • 6.2.6.8.1. By API
      • 6.2.6.8.2. By Manufacturer
      • 6.2.6.8.3. By Type of Drug
      • 6.2.6.8.4. By Therapeutic Area
      • 6.2.6.8.5. By Potency
      • 6.2.6.9. Rest of Europe
      • 6.2.6.9.1. By API
      • 6.2.6.9.2. By Manufacturer
      • 6.2.6.9.3. By Type of Drug
      • 6.2.6.9.4. By Therapeutic Area
      • 6.2.6.9.5. By Potency

7. Asia-Pacific Active Pharmaceutical Ingredients (API) Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By API
    • 7.2.2. By Manufacturer
    • 7.2.3. By Type of Drug
    • 7.2.4. By Therapeutic Area
    • 7.2.5. By Potency
    • 7.2.6. By Country
      • 7.2.6.1. China
      • 7.2.6.1.1. By API
      • 7.2.6.1.2. By Manufacturer
      • 7.2.6.1.3. By Type of Drug
      • 7.2.6.1.4. By Therapeutic Area
      • 7.2.6.1.5. By Potency
      • 7.2.6.2. India
      • 7.2.6.2.1. By API
      • 7.2.6.2.2. By Manufacturer
      • 7.2.6.2.3. By Type of Drug
      • 7.2.6.2.4. By Therapeutic Area
      • 7.2.6.2.5. By Potency
      • 7.2.6.3. Japan
      • 7.2.6.3.1. By API
      • 7.2.6.3.2. By Manufacturer
      • 7.2.6.3.3. By Type of Drug
      • 7.2.6.3.4. By Therapeutic Area
      • 7.2.6.3.5. By Potency
      • 7.2.6.4. South Korea
      • 7.2.6.4.1. By API
      • 7.2.6.4.2. By Manufacturer
      • 7.2.6.4.3. By Type of Drug
      • 7.2.6.4.4. By Therapeutic Area
      • 7.2.6.4.5. By Potency
      • 7.2.6.5. Australia & New Zealand
      • 7.2.6.5.1. By API
      • 7.2.6.5.2. By Manufacturer
      • 7.2.6.5.3. By Type of Drug
      • 7.2.6.5.4. By Therapeutic Area
      • 7.2.6.5.5. By Potency
      • 7.2.6.6. Indonesia
      • 7.2.6.6.1. By API
      • 7.2.6.6.2. By Manufacturer
      • 7.2.6.6.3. By Type of Drug
      • 7.2.6.6.4. By Therapeutic Area
      • 7.2.6.6.5. By Potency
      • 7.2.6.7. Malaysia
      • 7.2.6.7.1. By API
      • 7.2.6.7.2. By Manufacturer
      • 7.2.6.7.3. By Type of Drug
      • 7.2.6.7.4. By Therapeutic Area
      • 7.2.6.7.5. By Potency
      • 7.2.6.8. Singapore
      • 7.2.6.8.1. By API
      • 7.2.6.8.2. By Manufacturer
      • 7.2.6.8.3. By Type of Drug
      • 7.2.6.8.4. By Therapeutic Area
      • 7.2.6.8.5. By Potency
      • 7.2.6.9. Vietnam
      • 7.2.6.9.1. By API
      • 7.2.6.9.2. By Manufacturer
      • 7.2.6.9.3. By Type of Drug
      • 7.2.6.9.4. By Therapeutic Area
      • 7.2.6.9.5. By Potency
      • 7.2.6.10. Rest of APAC
      • 7.2.6.10.1. By API
      • 7.2.6.10.2. By Manufacturer
      • 7.2.6.10.3. By Type of Drug
      • 7.2.6.10.4. By Therapeutic Area
      • 7.2.6.10.5. By Potency

8. Latin America Active Pharmaceutical Ingredients (API) Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
      • 8.2.1.1. By API
      • 8.2.1.2. By Manufacturer
      • 8.2.1.3. By Type of Drug
      • 8.2.1.4. By Therapeutic Area
      • 8.2.1.5. By Potency
    • 8.2.2. By Country
      • 8.2.2.1. Brazil
      • 8.2.2.1.1. By API
      • 8.2.2.1.2. By Manufacturer
      • 8.2.2.1.3. By Type of Drug
      • 8.2.2.1.4. By Therapeutic Area
      • 8.2.2.1.5. By Potency
      • 8.2.2.2. Mexico
      • 8.2.2.2.1. By API
      • 8.2.2.2.2. By Manufacturer
      • 8.2.2.2.3. By Type of Drug
      • 8.2.2.2.4. By Therapeutic Area
      • 8.2.2.2.5. By Potency
      • 8.2.2.3. Argentina
      • 8.2.2.3.1. By API
      • 8.2.2.3.2. By Manufacturer
      • 8.2.2.3.3. By Type of Drug
      • 8.2.2.3.4. By Therapeutic Area
      • 8.2.2.3.5. By Potency
      • 8.2.2.4. Peru
      • 8.2.2.4.1. By API
      • 8.2.2.4.2. By Manufacturer
      • 8.2.2.4.3. By Type of Drug
      • 8.2.2.4.4. By Therapeutic Area
      • 8.2.2.4.5. By Potency
      • 8.2.2.5. Rest of LATAM
      • 8.2.2.5.1. By API
      • 8.2.2.5.2. By Manufacturer
      • 8.2.2.5.3. By Type of Drug
      • 8.2.2.5.4. By Therapeutic Area
      • 8.2.2.5.5. By Potency

9. Middle East & Africa Active Pharmaceutical Ingredients (API) Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By API
    • 9.2.2. By Manufacturer
    • 9.2.3. By Type of Drug
    • 9.2.4. By Therapeutic Area
    • 9.2.5. By Potency
    • 9.2.6. By Country
      • 9.2.6.1. Saudi Arabia
      • 9.2.6.1.1. By API
      • 9.2.6.1.2. By Manufacturer
      • 9.2.6.1.3. By Type of Drug
      • 9.2.6.1.4. By Therapeutic Area
      • 9.2.6.1.5. By Potency
      • 9.2.6.2. UAE
      • 9.2.6.2.1. By API
      • 9.2.6.2.2. By Manufacturer
      • 9.2.6.2.3. By Type of Drug
      • 9.2.6.2.4. By Therapeutic Area
      • 9.2.6.2.5. By Potency
      • 9.2.6.3. Qatar
      • 9.2.6.3.1. By API
      • 9.2.6.3.2. By Manufacturer
      • 9.2.6.3.3. By Type of Drug
      • 9.2.6.3.4. By Therapeutic Area
      • 9.2.6.3.5. By Potency
      • 9.2.6.4. Kuwait
      • 9.2.6.4.1. By API
      • 9.2.6.4.2. By Manufacturer
      • 9.2.6.4.3. By Type of Drug
      • 9.2.6.4.4. By Therapeutic Area
      • 9.2.6.4.5. By Potency
      • 9.2.6.5. South Africa
      • 9.2.6.5.1. By API
      • 9.2.6.5.2. By Manufacturer
      • 9.2.6.5.3. By Type of Drug
      • 9.2.6.5.4. By Therapeutic Area
      • 9.2.6.5.5. By Potency
      • 9.2.6.6. Nigeria
      • 9.2.6.6.1. By API
      • 9.2.6.6.2. By Manufacturer
      • 9.2.6.6.3. By Type of Drug
      • 9.2.6.6.4. By Therapeutic Area
      • 9.2.6.6.5. By Potency
      • 9.2.6.7. Algeria
      • 9.2.6.7.1. By API
      • 9.2.6.7.2. By Manufacturer
      • 9.2.6.7.3. By Type of Drug
      • 9.2.6.7.4. By Therapeutic Area
      • 9.2.6.7.5. By Potency
      • 9.2.6.8. Rest of MEA
      • 9.2.6.8.1. By API
      • 9.2.6.8.2. By Manufacturer
      • 9.2.6.8.3. By Type of Drug
      • 9.2.6.8.4. By Therapeutic Area
      • 9.2.6.8.5. By Potency

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Active Pharmaceutical Ingredients (API) Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Active Pharmaceutical Ingredients Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Teva Pharmaceutical Industries Ltd
  • 12.2. Pfizer Inc.
  • 12.3. Novartis International AG
  • 12.4. Mylan N.V.
  • 12.5. Aurobindo Pharma Ltd
  • 12.6. Sun Pharmaceutical Industries Ltd
  • 12.7. Boehringer Ingelheim GmbH
  • 12.8. Dr. Reddy's Laboratories Ltd
  • 12.9. Merck & Co., Inc.
  • 12.10. Lonza Group Ltd
  • 12.11. Bristol-Myers Squibb
  • 12.12. GlaxoSmithKline plc
  • 12.13. AbbVie Inc.
  • 12.14. Lupin Limited
  • 12.15. Cipla Ltd
  • 12.16. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations